72 related articles for article (PubMed ID: 26952881)
21. Oleic acid decreases BCRP mediated efflux of mitoxantrone in Caco-2 cell monolayers.
Aspenström-Fagerlund B; Tallkvist J; Ilbäck NG; Glynn AW
Food Chem Toxicol; 2012 Oct; 50(10):3635-45. PubMed ID: 22819932
[TBL] [Abstract][Full Text] [Related]
22. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract.
Gutmann H; Hruz P; Zimmermann C; Beglinger C; Drewe J
Biochem Pharmacol; 2005 Sep; 70(5):695-9. PubMed ID: 15998509
[TBL] [Abstract][Full Text] [Related]
23. Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells.
Kamiyama E; Sugiyama D; Nakai D; Miura S; Okazaki O
Drug Metab Dispos; 2009 Sep; 37(9):1956-62. PubMed ID: 19505989
[TBL] [Abstract][Full Text] [Related]
24. pH-Dependent transport of pemetrexed by breast cancer resistance protein.
Li L; Sham YY; Bikadi Z; Elmquist WF
Drug Metab Dispos; 2011 Sep; 39(9):1478-85. PubMed ID: 21628496
[TBL] [Abstract][Full Text] [Related]
25. Antipsychotic drugs inhibit the function of breast cancer resistance protein.
Wang JS; Zhu HJ; Markowitz JS; Donovan JL; Yuan HJ; Devane CL
Basic Clin Pharmacol Toxicol; 2008 Oct; 103(4):336-41. PubMed ID: 18834354
[TBL] [Abstract][Full Text] [Related]
26. Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype.
Prasad B; Lai Y; Lin Y; Unadkat JD
J Pharm Sci; 2013 Mar; 102(3):787-93. PubMed ID: 23280364
[TBL] [Abstract][Full Text] [Related]
27. Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate.
Ebert B; Seidel A; Lampen A
Toxicol Sci; 2007 Apr; 96(2):227-36. PubMed ID: 17077187
[TBL] [Abstract][Full Text] [Related]
28. Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP).
Liao M; Chuang BC; Zhu Q; Li Y; Guan E; Yu S; Yang J; Prakash S; Xia CQ
Xenobiotica; 2018 May; 48(5):467-477. PubMed ID: 28485193
[TBL] [Abstract][Full Text] [Related]
29. The Effect of Albumin on MRP2 and BCRP in the Vesicular Transport Assay.
Deng F; Sjöstedt N; Kidron H
PLoS One; 2016; 11(10):e0163886. PubMed ID: 27706255
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
Li Y; Woo J; Chmielecki J; Xia CQ; Liao M; Chuang BC; Yang JJ; Guan MY; Plesescu M; Prakash SR
Bioorg Med Chem Lett; 2016 Jan; 26(2):551-555. PubMed ID: 26642765
[TBL] [Abstract][Full Text] [Related]
31. Expression and Activity of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Distal Lung Epithelial Cells In Vitro.
Nickel S; Selo MA; Fallack J; Clerkin CG; Huwer H; Schneider-Daum N; Lehr CM; Ehrhardt C
Pharm Res; 2017 Dec; 34(12):2477-2487. PubMed ID: 28470471
[TBL] [Abstract][Full Text] [Related]
32. Sulfonation Disposition of Acacetin: In Vitro and in Vivo.
Zhang Q; Zhu L; Gong X; Ruan Y; Yu J; Jiang H; Wang Y; Qi X; Lu L; Liu Z
J Agric Food Chem; 2017 Jun; 65(24):4921-4931. PubMed ID: 28540728
[TBL] [Abstract][Full Text] [Related]
33. [Role of breast cancer resistance protein in drug disposition].
Wu XM; Sheng L; Jia YF; Li Y
Yao Xue Xue Bao; 2016 Sep; 51(9):1368-77. PubMed ID: 29924510
[TBL] [Abstract][Full Text] [Related]
34. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations.
Mutsaers HA; van den Heuvel LP; Ringens LH; Dankers AC; Russel FG; Wetzels JF; Hoenderop JG; Masereeuw R
PLoS One; 2011 Apr; 6(4):e18438. PubMed ID: 21483698
[TBL] [Abstract][Full Text] [Related]
35. R- and S-Warfarin Were Transported by Breast Cancer Resistance Protein: From In Vitro to Pharmacokinetic-Pharmacodynamic Studies.
Yang MS; Yu CP; Chao PL; Lin SP; Hou YC
J Pharm Sci; 2017 May; 106(5):1419-1425. PubMed ID: 28093289
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 Tat Protein Enhances Expression and Function of Breast Cancer Resistance Protein.
Zhou Y; Zhang K; Yin X; Nie Q; Ma Y
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):1-3. PubMed ID: 26367065
[TBL] [Abstract][Full Text] [Related]
37. Hyperuricemia enhances intracellular urate accumulation via down-regulation of cell-surface BCRP/ABCG2 expression in vascular endothelial cells.
Komori H; Yamada K; Tamai I
Biochim Biophys Acta Biomembr; 2018 May; 1860(5):973-980. PubMed ID: 29317200
[TBL] [Abstract][Full Text] [Related]
38. Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter.
Sawangrat K; Yamashita S; Tanaka A; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
J Pharm Sci; 2019 Mar; 108(3):1315-1325. PubMed ID: 30389568
[TBL] [Abstract][Full Text] [Related]
39. Expression of membrane transporters and metabolic enzymes involved in estrone-3-sulphate disposition in human breast tumour tissues.
Banerjee N; Miller N; Allen C; Bendayan R
Breast Cancer Res Treat; 2014 Jun; 145(3):647-61. PubMed ID: 24831777
[TBL] [Abstract][Full Text] [Related]
40. Disposition of Mianserin and Cyclizine in UGT2B10-Overexpressing Human Embryonic Kidney 293 Cells: Identification of UGT2B10 as a Novel N-Glucosidation Enzyme and Breast Cancer Resistance Protein as an N-Glucoside Transporter.
Lu D; Dong D; Xie Q; Li Z; Wu B
Drug Metab Dispos; 2018 Jul; 46(7):970-979. PubMed ID: 29691239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
